Biomedical Engineering Reference
In-Depth Information
229. Schroeder, A.; Honen, R.; Turjeman, K.; Gabizon, A.; Kost, J.; Barenholz, Y. Ultrasound Trig-
gered Release of Cisplatin from Liposomes in Murine Tumors.
J. Controlled Release
2009,
37,
63-68.
230. Zhao, H.; Li, G. L.; Wang, R. Z.; Li, S. F.; Wei, J. J.; Feng, M., et al. A Comparative Study of
Transfection Efficiency between Liposomes, Immunoliposomes and Brain-specific Immuno-
liposomes.
J. Int. Med. Res.
2010,
38,
957-966.
231. Gordon, A. N.; Granai, C. O.; Rose, P. G.; Hainsworth, J.; Lopez, A.; Weissman, C., et al.
Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxelrefractory Epithelial
Ovarian Cancer.
J. Clin. Oncol.
2000,
18,
3093-3100.
232. Ranson, M. R.; Carmichael, J.; O'Byrne, K.; Stewart, S.; Smith, D.; Howell, A. Treatment
of Advanced Breast Cancer with Sterically Stabilized Liposomal Dox-orubicin: Results of a
Multicenter Phase II Trial.
J. Clin. Oncol.
1997,
15,
3185-3191.
233. Ahmed, M.; Monsky, W. E.; Girnun, G.; Lukyanov, A.; D'Ippolito, G.; Kruskal, J. B., et al.
Radiofrequency Thermal Ablation Sharply Increases Intratumoral Liposomal Doxorubicin
Accumulation and Tumor Coagulation.
Cancer Res.
2003,
63,
6327-6333.
234. Ahmed, F.; Pakunlu, R. I.; Srinivas, G.; Brannan, A.; Bates, F.; Klein, M. L.; Minko, T.;
Discher, D. E. Shrinkage of a Rapidly Growing Tumor by Drug-loaded Polymersomes: pH-
triggered Release Through Copolymer Degradation.
Mol. Pharm.
2006,
3,
340-350.
235. Monsky, W. L.; Kruskal, J. B.; Lukyanov, A. N.; Girnun, G. D.; Ahmed, M.; Gazelle, G. S.,
et al. Radio-frequency Ablation Increases Intratumoral Liposomal Doxorubicin Accumulation
in a Rat Breast Tumor Model.
Radiology
2002,
224,
823-829.
236. Goldberg, S. N.; Kamel, I. R.; Kruskal, J. B.; Reynolds, K.; Monsky, W. L.; Stuart, K. E., et al.
Radiofrequency Ablation of Hepatic Tumors: Increased Tumor Destruction with Adjuvant
Liposomal Doxorubicin Therapy.
Am. J. Roentgenol.
2002,
179,
93-101.
237. Brantley Sieders, D.; Schmidt, S.; Parker, M.; Chen, J. Eph Receptor Tyrosinekinases in
Tumor and Tumor Microenvironment.
Curr. Pharm. Des.
2004,
20,
3431-3442.
238. Brindle, K. New Approaches for Imaging Tumour Responses to Treatment.
Nat. Rev. Cancer
2008,
8,
94-107.
239. Kirchin, M. A.; Runge, V. M. Contrast Agents for Magnetic Resonance Imaging: Safety
Update.
Top Magn. Reson. Imaging
2003,
14,
426-435.
240. Emerich, D. F.; Thanos, C. G.; Emerich, D. F.; Thanos, C. G. Targeted Nanoparticle Based
Drug Delivery and Diagnosis.
J. Drug Target.
2007,
15,
163-183.
241. Groneberg, D. A.; Giersig, M.; Welte, T.; Pison, U. Nanoparticle Based Diagnosis and Ther-
apy.
Curr. Drug Target.
2006,
7,
643-648.
242. Jain, T. K.; Reddy, M. K.; Morales, M. A.; LesliePelecky, D. L.; Labhasetwar, V. Biodistribu-
tion, Clearance, and Biocompatibility of Iron Oxide Magnetic Nanoparticles in Rats.
Mol.
Pharm.
2008,
5,
316-327.
243. Simonsen, C. Z.; Ostergaard, L.; VestergaardPoulsen, P.; Rohl, L.; Bjornerud, A.; Gyldensted,
C. CBF and CBV Measurements by USPIO Bolus Tracking: Reproducibility and Comparison
with Gd Based Values.
J. Magn. Reson. Imaging
1999,
9,
342-347.
244. Okon, E.; Pouliquen, D.; Okon, P.; Kovaleva, Z. V.; Stepanova, T. P.; Lavit, S. G.; Kudryavtsev,
B. N.; Jallet, P. Biodegradation of Magnetite Dextran Nanoparticles in the Rat: a Histologic
and Biophysical Study.
Am. J. Roentgenol.
1994,
71,
895-903.
245. Runge, V. M.
Contrast Agents Safety Profile,
, 2008 (accessed jun 18, 2012) Available from:
http://
246. Coyne, D. W. Ferumoxytol for Treatment of Iron Deficiency Anemia in Patients with Chronic
Kidney Disease.
Expert Opin. Pharmacother.
2009,
10,
2563-2568.
